Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening
Open Access
- 4 September 2012
- journal article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 12 (1), 300
- https://doi.org/10.1186/1472-6963-12-300
Abstract
Economic evaluation of newborn screening poses specific methodological challenges. Amongst others, these challenges refer to the use of quality adjusted life years (QALYs) in newborns, and which costs and outcomes need to be considered in a full evaluation of newborn screening programmes. Because of the increasing scale and scope of such programmes, a better understanding of the methods of high-quality economic evaluations may be crucial for both producers/authors and consumers/reviewers of newborn screening-related economic evaluations. The aim of this study was therefore to develop specific guidelines designed to assess and improve the methodological quality of economic evaluations in newborn screening.Keywords
This publication has 84 references indexed in Scilit:
- Challenges in Health State Valuation in Paediatric Economic EvaluationPharmacoEconomics, 2011
- Development of the EQ-5D-Y: a child-friendly version of the EQ-5DQuality of Life Research, 2010
- Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational studyQuality of Life Research, 2010
- 30 Years of Pharmaceutical Cost-Utility AnalysesPharmacoEconomics, 2009
- On future non‐medical costs in economic evaluationsHealth Economics, 2007
- Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in ChildrenPharmacoEconomics, 2007
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Valuing Patient and Caregiver TimePharmacoEconomics, 2005
- A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between CountriesPharmacoEconomics, 2004
- Assessing Quality in Decision Analytic Cost-Effectiveness ModelsPharmacoEconomics, 2000